Literature DB >> 24577752

Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues.

Ben-Dong Chen1, Wen-Chao Zhao, Jian-Da Dong, Hui Sima.   

Abstract

The study investigates the expression and clinical role of GLP-1R in intrahepatic cholangiocarcinoma (ICC) tissues. ICC tissue, tissue around tumour and normal liver tissue samples from 176 ICC patients were investigated for GLP-1R expression by immunohistochemistry and western blots. Expression levels were correlated to clinical variables and to the postoperative outcome. High GLP-1R expression levels were detected in tumor tissue samples. Kaplan-Meier method was used for survival analysis of patients follow-up data. Results showed that median survival time of patients with high GLP-1R positive expression in ICC tissue were 22 months. Median survival time of patients with low GLP-1R positive expression in ICC tissue were 19.8 months. There wasn't statistical difference (p = 0.332) between two groups. Immunohistochemistry semi-quantitative analysis showed that tissue differentiation is not prognostic risk factors. In patients with GLP-1R positive expression in ICC tissue, lymph node metastasis was important prognostic factors (p = 0.001). Although statistical analysis showed that GLP-1R can not be judged as a risk prognostic factors, GLP-1 might become a new target for therapy of ICC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24577752     DOI: 10.1007/s11033-014-3302-7

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  43 in total

Review 1.  Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment.

Authors:  M F Chen
Journal:  J Gastroenterol Hepatol       Date:  1999-12       Impact factor: 4.029

2.  Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.

Authors:  Tania M Welzel; Barry I Graubard; Stefan Zeuzem; Hashem B El-Serag; Jessica A Davila; Katherine A McGlynn
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

3.  Insulin-like growth factor binding protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCAR3 human epithelial ovarian cancer cells.

Authors:  Shilla Chakrabarty; Laura Kondratick
Journal:  Cancer Biol Ther       Date:  2006-02-15       Impact factor: 4.742

4.  Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential.

Authors:  U Broomé; R Löfberg; B Veress; L S Eriksson
Journal:  Hepatology       Date:  1995-11       Impact factor: 17.425

Review 5.  Epidemiology of cholangiocarcinoma: an update focusing on risk factors.

Authors:  Hai-Rim Shin; Jin-Kyoung Oh; Eric Masuyer; Maria-Paula Curado; Veronique Bouvard; Yue-Yi Fang; Surapon Wiangnon; Banchob Sripa; Sung-Tae Hong
Journal:  Cancer Sci       Date:  2009-12-04       Impact factor: 6.716

6.  Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China.

Authors:  Yan-Ming Zhou; Zheng-Feng Yin; Jia-Mei Yang; Bin Li; Wen-Yu Shao; Feng Xu; Yu-Lan Wang; Dian-Qi Li
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

7.  Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma.

Authors:  Satoshi Yamamoto; Shoji Kubo; Seikan Hai; Takahiro Uenishi; Takatsugu Yamamoto; Taichi Shuto; Shigekazu Takemura; Hiromu Tanaka; Osamu Yamazaki; Kazuhiro Hirohashi; Takashi Tanaka
Journal:  Cancer Sci       Date:  2004-07       Impact factor: 6.716

8.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.

Authors:  Tania M Welzel; Barry I Graubard; Hashem B El-Serag; Yasser H Shaib; Ann W Hsing; Jessica A Davila; Katherine A McGlynn
Journal:  Clin Gastroenterol Hepatol       Date:  2007-08-06       Impact factor: 11.382

9.  The association between diabetes, insulin use, and colorectal cancer among Whites and African Americans.

Authors:  Lisa C Vinikoor; Millie D Long; Temitope O Keku; Christopher F Martin; Joseph A Galanko; Robert S Sandler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-31       Impact factor: 4.254

10.  Intrahepatic cholangiocarcinoma: impact of genetic hemochromatosis on outcome and overall survival after surgical resection.

Authors:  Laurent Sulpice; Michel Rayar; Eveline Boucher; Fabienne Pele; Marc Pracht; Bernard Meunier; Karim Boudjema
Journal:  J Surg Res       Date:  2012-11-20       Impact factor: 2.192

View more
  6 in total

1.  Oxaliplatin reverses the GLP-1R-mediated promotion of intrahepatic cholangiocarcinoma by altering FoxO1 signaling.

Authors:  Bendong Chen; Wenyan Zhou; Wenchao Zhao; Peng Yuan; Chaofeng Tang; Genwang Wang; Junzhi Leng; Jinlong Ma; Xiaowen Wang; Yongfeng Hui; Qi Wang
Journal:  Oncol Lett       Date:  2019-06-19       Impact factor: 2.967

2.  Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.

Authors:  Devin Abrahami; Antonios Douros; Hui Yin; Oriana Hy Yu; Jean-Luc Faillie; François Montastruc; Robert W Platt; Nathaniel Bouganim; Laurent Azoulay
Journal:  BMJ       Date:  2018-12-05

Review 3.  DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits.

Authors:  Michael Razavi; Ying-Ying Wei; Xiao-Quan Rao; Ji-Xin Zhong
Journal:  Mil Med Res       Date:  2022-08-20

Review 4.  The role of insulin and incretin-based drugs in biliary tract cancer: epidemiological and experimental evidence.

Authors:  Hua Sun; Xiaohui Qi
Journal:  Discov Oncol       Date:  2022-08-07

Review 5.  CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology.

Authors:  Emi Kawakita; Daisuke Koya; Keizo Kanasaki
Journal:  Cancers (Basel)       Date:  2021-05-02       Impact factor: 6.639

6.  Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study.

Authors:  Peter Ueda; Viktor Wintzell; Mads Melbye; Björn Eliasson; Ann-Marie Svensson; Stefan Franzén; Soffia Gudbjörnsdottir; Kristian Hveem; Christian Jonasson; Henrik Svanström; Björn Pasternak
Journal:  Diabetologia       Date:  2021-07-13       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.